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Osteogenic potentials of some recombinant human bone morphogenetic protein (BMP) first-generation 
adenoviral vectors (ADhBMPs) are significantly limited in immunocompetent animals. It is unclear what role 
expression of viral proteins and foreign proteins transduced by adenoviral vectors play in the host immune 
response and in ectopic bone formation. In this study two sets of experiments were designed and performed. 
First, rat BMP6 cDNA were amplified, sequenced, and recombined in first-generation adenoviral vector 
(ADrBMP6). A comparison of human and rat BMP6 adenoviral vectors demonstrated identical osteogenic 
activities in both immunodeficient and immunocompetent rats. Second, the activities of recombinant human 
BMP6 in E1- (ADhBMP6) and [E1-,E2b-] ( [E1-,E2b-]ADGFP&hBMP6, and [E1-,E2b-]ADhBMP6) adenoviral 
vectors were compared in both in vitro and in vivo models. Similar activities of these two generations of BMP 
adenoviral vectors were found in all models. These results indicate that the amount of viral gene expression and 
the source of the BMP cDNA are not major factors in the interruption of osteogenic potentials of recombinant 
BMP6 adenoviral vectors in immunocompetent animals.  
1.  INTRODUCTION 
Gene therapy provides a novel method to repair 
damaged bone by using bone morphogenetic protein 
(BMP). BMP gene vectors can be divided into DNA, 
viral, and cell vectors [10, 19]. Among the BMP gene 
therapy vectors, human BMP adenoviral vectors 
(ADhBMPs) are very commonly used and have 
displayed strong osteogenic potentials in 
immunodeficient animals [1, 25]. Nevertheless, the 
functions of ADhBMPs have proved to be significantly 
limited in immunocompetent animals [1, 25, 35, 38]. 
All five human BMP adenoviral vectors (ADhBMPs 2, 
4, 6, 7, and 9) have been shown to induce large 
volumes of ectopic bone formation in athymic nude 
(AN) rats. Bone volumes induced by these BMP 
vectors were greatest when ADhBMPs 4, 6, and 9 were 
used, followed by ADhBMP2 and, finally, by 
ADhBMP7. The osteogenic potentials of ADhBMPs 2, 
4, and 7, however, were not shown in 
immunocompetent animals. In addition, bone 
volumes induced by ADhBMP6 were significantly 
smaller in immunocompetent animals than in 
immunodeficient animals. In contrast, bone formation 
induced by ADhBMP9 was similar in AN and 
immunocompetent rats [25]. These results may be 
related to different BMP signal transduction pathways 
and the host immune response. 
The BMP family includes more than 30 members 
[9, 46]. According to previous studies, BMPs combine 
with type 1 (Alk2, Alk3, and Alk6) and type 2 (BR2, 
ActR2, and ActR2B) receptors, activate the Smad and 
p38/MAPK signal transduction pathways, and, finally, 
activate transcription of bone formation factors  [36, 
44]. BMP2 and BMP4 combine with Alk3 and use 
Smad1, Smad5, or Smad8 to transduce signals  [4, 31]. 
BMP6 and BMP7 may strongly combine with Alk2 
and weakly combine with Alk3 and Alk6. Their 
signals are mainly transferred with Smad5 and, 
possibly, with Smad1 but not with Smad8  [11, 13]. 
Compared with other BMPs, BMP9 uses a different 
type of receptor and signal transduction pathway, the 
details of which are not yet clear  [30, 40]. The 
functional performances of various BMP adenoviral 
vectors may reflect different mechanisms in vivo.  
The host immune response to an adenovirus and 
its infected cells may be a primary cause of this 
functional limitation. The antigenicity of adenoviral 
vectors, which induce the host immune response, 
consist of directly injected viral particles and viral 
genome–expressed proteins that include viral proteins 
and foreign transgene-encoded proteins  [27, 42]. It is 
unclear what roles expression of viral proteins and 
foreign proteins transduced by adenoviral vectors 
play in the host immune response and ectopic bone 
formation. The adenoviral genome can be divided into 
four early regions: E1, E2, E3, and E4 [6]. Adenoviral 
vectors in which the E1 and E3 regions have been 
deleted have commonly been used in the field of gene 
therapy and are called first-generation adenoviral 
vectors, that is, replication-defective adenoviruses. Int. J. Med. Sci. 2006, 3  98
Unfortunately, because of the presence of E1-like 
factors in many cell types, vectors with the E1 deletion 
may still express a certain amount of viral gene 
products  in vivo. The expression of viral proteins in 
infected target cells may increase the host immune 
response and further interrupt the expression of the 
foreign gene [12]. To limit the productions of 
potentially immunogenic viral proteins, investigators 
have pursued the construction of adenoviral vectors in 
which more or even all viral coding genes have been 
deleted. Helper-dependent adenoviral  vectors in 
which all viral protein–coding DNA sequences have 
been deleted have been developed [34, 45]. This 
modification reportedly has reduced toxicity and 
prolonged gene expression in some experiments [5, 
33]. Nevertheless, we constructed a recombinant 
BMP9 helper-dependent adenoviral vector and found 
that the osteogenic potentials of this vector were not 
significantly different from those of the corresponding 
recombinant BMP9 first-generation vector (ADhBMP9) 
in immunodeficient and immunocompetent rats [23]. 
Because there are different signal transduction 
pathways among the BMPs, the complex procedure 
needed to produce the helper-dependent vector and 
the possible roles of viral gene products in the process 
of bone formation need to be clarified further. An 
adenoviral vector with deletions of E1, E3, and the 
polymerase and terminal protein ( [E1-,E2b-]AD, also 
known as the second-generation adenoviral vector) 
was selected in the following study. This class of 
modified adenovirus vector has several potential 
benefits including the following: 1) clonal 
preparations that do not require a helper virus for 
growth; 2) theoretically, decreased frequency of 
replication-competent adenovirus generation; 3) 
increased carrying capacity; 4) rapid scale up of 
production; and 5) decreased potential for eliciting an 
immunogenic response in vivo  [20]. On the other hand, 
the sources of BMP cDNAs may also cause the 
functional limitation of ADhBMPs in 
immunocompetent animals. We selected rat BMP4 
and BMP6 to help us answer these questions. 
In the present study, two different sets of 
experiments were designed and performed. In the first, 
rat BMP6 cDNA from adult Sprague–Dawley (SD) rats 
was cloned and sequenced. A recombinant first-
generation adenovirus ADrBMP6 was constructed and 
compared with ADhBMP6 in the process of bone 
formation. In the second set of experiments, human 
BMP6 cDNA was constructed to form a second-
generation human BMP adenoviral vector ( [E1-,E2b-
]ADhBMP). The viral vectors [E1-,E2b-]ADhBMP6, 
and [E1-,E2b-]ADGFP&BMP6 which include the green 
fluorescent protein [GFP] were tested in in vitro and in 
vivo models. The roles of the viral genome and the 
sources of BMP cDNA in the process of bone 
formation were determined in this study.  
2.  MATERIALS AND METHODS 
Cloning and identification of rat BMP4 and BMP6 cDNA 
coding sequences 
Total RNA was prepared from the spleen of a 2-
month-old SD rat by using an RNeasy Mini Kit 
(Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. Rat BMP4 and BMP6 
cDNAs containing full coding sequences were 
generated by performing an RT-PCR with the OneStep 
RT-PCR Kit (Qiagen). The designs of the PCR primers 
were based on a known rat BMP4 sequence and a 
partial rat BMP6 sequence in which mouse and 
human  BMP6 sequences were inserted in places in 
which the rat sequence was not known  [17, 22, 39]. 
For  BMP4, the upstream primer was 5´–CCA CCA 
TGA TTC CTG GTA ACC GAA TGC TG–3´, to which 
CCACC was added to give the amplified product a 
typical Kozak consensus sequence around the initiator 
methionine; the downstream primer was 5´–CTC AGC 
GGC ATC CGC ACC CCT C–3´. For BMP6, the 
upstream primer was 5´–TTAGAT CTC CAC CAT 
GCC CGG GCT GGG G–3´, and the downstream 
primer was 5´–AGA ATC ACA GCC CCT GCA A–3´. 
Single PCR products of the expected size (1.2 kb for 
BMP4  and 1.5 kb for BMP6) were purified by 
performing agarose gel electrophoresis and cloned 
into the EcoRV site of pShuttleCMV after having been 
blunted with T4 DNA polymerase. The purified rat 
BMP4 and BMP6 PCR products and the recombinant 
plasmids of pShuttle-rBMP4 and pShuttle-rBMP6 
were prepared and sequenced (both strands) to ensure 
that the rat BMP inserts were correct.  
Construction of rat BMP4 and BMP6 recombinant 
adenoviruses  
The AdEasy Vector System [18] was used for 
construction of the rat BMP4 and BMP6 adenoviral 
vectors. The linear pShuttle-rBMPs and the pAdEasy 1 
plasmid were cotransformed into the competent 
Escherichia coli strain BJ5183 to obtain the BMP viral 
DNA plasmid. Briefly, 1 µg of linearized recombinant 
transfer vector pShuttle-rBMP (5 µl) and 1.0 µl of 
pAdEasy-1 vector (100 ng/µl) were added to 200 µl of 
competent BJ5183 cells. The next procedure followed 
methods outlined in previous reports  [18]. The 
recombinant clones were identified by using a PCR. 
The pAdeasy-1 contains the human adenovirus 
type 5 genome with E1 and E3  deletions.  The 
recombinant adenoviral plasmids, pADrBMP4 and 
pADrBMP6, were cleaved with PacI to expose their 
inverted terminal repeats and transfected into 293A 
cells to produce viral particles. The recombinant 
viruses were identified by performing PCR, RT-PCR, 
Southern blot analysis, immunocytochemical staining, 
and Western blot analysis. The recombinant 
ADrBMP4 and ADrBMP6 were purified through two 
cesium chloride gradients, after which the purified 
virus was desalted by dialysis at 4°C against 10 mM 
Tris–hydrochloric acid buffer with 10% glycerol and 
stored in aliquots in liquid nitrogen. The titer of the 
virus preparations was determined by measuring the Int. J. Med. Sci. 2006, 3  99
spectrophotometric absorbance at 260 nm and by 
performing a plaque assay. 
The AdEasy1ΔpolΔpTpsmall Vector System ( [E1-
,E2b-]AD) [3] was used for construction of human 
BMP second-generation adenoviral vectors ( [E1-,E2b-
]ADhBMP6, [E1-,E2b-]ADGFP&hBMP4, and [E1-,E2b-
]ADGFP&hBMP6), which lack polymerase and 
terminal protein [E2b] as well as the E1 and E3 genes. 
Human  BMP4 cDNA was inserted into the shuttle 
vector pTrackCMV, and a recombinant adenoviral 
vector was made that encoded both GFP and human 
BMP4 ( [E1-,E2b-]ADGFP&hBMP4). Human BMP6 
cDNA was inserted into the shuttle vectors 
pShuttleCMV and pTrackCMV, and recombinant 
adenoviral vectors were made that encode human 
BMP6 with GFP ( [E1-,E2b-]ADGFP&hBMP6) and 
without GFP ( [E1-,E2b-]ADhBMP6), as described 
earlier for the AdEasy Vector System. The viruses 
were produced in C7 cells, which are stably 
transformed with adenoviral E1 and E2b genes  [2]. 
The viral titer was measured by determining the 
spectrophotometric absorbance at 260 nm.  
Southern blot analysis of genomic DNA of recombinant 
adenovirus 
Viral DNA was isolated from 293A or C7 cells 
that had been transduced with recombinant 
adenovirus. One hundred nanograms of each DNA 
was digested with HindIII, BstXI (BMP4 and BMP6), 
or  BglII plus EcoRV (BMP6); electrophoretically 
separated in a 0.8% agarose gel; and transferred onto a 
nylon membrane. The membranes were baked at 80°C 
for 30 min and probed with the pAdEasy1 plasmid, 
BMP4 cDNA fragment, or BMP6 cDNA fragment, 
each of which was labeled with digoxigenin by using 
the DIG-Chem-Link Labeling and Detection Set 
(Roche Diagnostics Corp., Indianapolis, IN). Detection 
of DIG-labeled nucleic acids was performed using the 
DIG Luminescent Detection Kit (Roche). 
Western blot detection of BMP4 and BMP6 
The pShuttle-rBMP4 and pShuttle-rBMP6 
plasmids were transfected into 293A cells with 
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, 
CA). African green monkey kidney cells (Vero cells, 
No. CCL-81; American Type Culture Collection 
[ATCC], Manassas, VA), which have a higher 
potential to produce BMPs than 293A or C2C12 cells, 
were infected with ADrBMP4, ADhBMP4 [25], [E1-
,E2b-]ADGFP&hBMP4, ADrBMP6, ADhBMP6 [25], 
[E1-,E2b-]ADhBMP6, [E1-,E2b-]ADGFP&hBMP6, or 
ADNULL (2 × 108 particles per well of a 24-well plate) 
in Opti-MEMI medium without fetal bovine serum. 
After transfection, the 293A cells or infected Vero cells 
were incubated for 48 hrs at 37°C. The transfected cells 
and media were harvested, treated in LDS sample 
buffer (Invitrogen) at 70°C for 10 min with reducing 
reagent (Invitrogen Corp., Carlsbad, CA), 
electrophoresed on a NuPAGE 10% Bis-Tris System 
(Invitrogen), and transferred to a PVDF membrane 
(Invitrogen). Recombinant human BMP4 and BMP6 
(R&D Systems, Minneapolis, MN) were used as 
standard proteins. The blots were reacted with 
monoclonal mouse BMP4 or BMP6 antibody 
(Chemicon, Temecula, CA) at 1 μg/ml or with mouse 
β-actin antibody (Sigma Chemical Co, St. Louis, MO) 
at a 1:5000 dilution. The Novex Chemiluminescent 
Western Blotting Immunodetection System 
(Invitrogen) was used.  Three concentrations of 
standard BMPs were used to make the standard 
curves. We calculated the sample BMP concentrations 
based on the results of film scanning by using the 
Personal Densitometer SI (Amersham Biosciences, 
Piscataway, NJ). 
Rat BMP4 and BMP6 biological activity assays.  
Mouse C2C12 myoblastic cells (No. CRL-1772; 
ATCC) were used in bioassays to determine the 
biological activity of the BMPs. We chose the C2C12 
cell line for this experiment not only because increased 
ALP activity in these cells is dependent on stimulation 
by BMPs, but also because the C2C12 cell has a lower 
background of ALP and constitutes a defined cell line 
that is much more convenient to use than human 
mesenchymal stem cells. Cells in 48-well plates that 
had reached 80% to 90% confluence were infected 
with ADrBMP4, ADhBMP4, ADrBMP6, ADhBMP6, or 
ADNULL at concentrations of 3 × 108, 1.5 × 108, 7.5 × 
107, and 3.8 × 107 particles per well. Seven days later, 
the cells were stained to measure ALP by using the 
Sigma Diagnostics ALP Kit (Sigma Diagnostics, Inc., St. 
Louis, MO). 
In vivo ectopic bone formation in rats 
We studied ectopic bone formation in 2-month-
old male rats. Eight AN rats and 20 SD rats were used 
for the study of BMP4, and 16 AN rats and 21 SD rats 
for the study of BMP6. Animal protocols were 
approved by the University of Virginia Animal Use 
and Research Committee and conformed to National 
Institutes of Health guidelines. The rats were 
anesthetized with a mixture of ketamine and xylazine, 
and in each animal the thigh was prepared in a sterile 
fashion. Using a 19-gauge guide needle, the skin 1 cm 
above the knee joint was punctured and the needle 
advanced 1 cm proximally. Through this needle, a 
Hamilton microsyringe was inserted and 50 μl of viral 
solution (2.8 × 1010, 5 × 1010, or 1.4 × 1011 particles) was 
injected. 
For BMP4, the AN rats were separated into two 
groups (four rats per group). Animals in the first 
group received an injection of ADrBMP4 in one thigh 
and an injection of ADNULL in the other. Animals in 
the other group received an injection of [E1-,E2b-
]ADGFP&hBMP4 in one thigh and an injection of 
ADhBMP4 in the other. Each injection contained 5 × 
1010 particles. The SD rats were separated into four 
groups (5 animals in each group). These animals 
received bilateral injections (5 × 1010 particles in one 
thigh and 1 × 1010 particles in the other) of ADNULL, 
ADhBMP4, ADrBMP4, or [E1-,E2b-] ADGFP&hBMP4. 
For BMP6, the AN rats were separated into four 
groups (four rats per group). Animals in three groups 
received an injection of 2.8 × 1010 particles of Int. J. Med. Sci. 2006, 3  100
ADNULL in one thigh and an injection of 2.8 × 1010 
particles of either ADhBMP6, [E1-,E2b-
]ADGFP&hBMP6, or [E1-,E2b-]ADhBMP6 in the other 
thigh. Animals in the remaining group were injected 
in one thigh with 1.4 × 1011 of ADrBMP6 particles and 
in the other thigh with 2.8 × 1010 particles of ADrBMP6. 
The SD rats were separated into five groups. Only one 
vector was injected into each SD rat. Animals in the 
first four groups (four rats per group) received 
bilateral injections of either ADNULL, ADhBMP6, [E1-
,E2b-]ADGFP&hBMP6, or [E1-,E2b-]ADhBMP6 (2.8 × 
1010 particles per thigh). The other five rats received 
bilateral injections of ADrBMP6 (2.8 × 1010 particles in 
one thigh and 1.4 × 1011 particles in the other thigh). 
On Day 35, the rats were euthanized and scanned 
using CT. Axial CT images (1-mm collimation and 1-
mm table increment) were obtained using the 
standard algorithm with 130 kV, 100 mA, a 2-second 
scan time, and a 40-mm image size. The three-
dimensional reconstruction was performed using a 
Voxel Q workstation. Serum samples were collected 
on Days 0 and 35.  
Detection of antibodies to adenovirus  
Ninety-six-well Nunc Maxisorb plates (Nunc, 
Inc., Roskilde, Demark) were coated with 100 μl of 
purified adenovirus (5 × 109 particles AdCMV-
βgal/ml) in phosphate-buffered saline (PBS) overnight 
at 4°C, washed four times in PBS containing 0.05% 
Tween-20, and blocked in PBS supplemented with 1% 
bovine serum albumin for 1 hr at 37°C. Appropriately 
diluted serum samples were added to antigen-coated 
plates and incubated overnight at 4°C. Plates were 
washed four times in PBS–0.05% Tween-20 and 
incubated with anti–rat IgG (H+L) ALP conjugate 
(1:2500 dilution, Promega, Madison, WI) for 2 hrs at 
37°C. The plates were washed in the manner 
described earlier, and ρ-nitrophenyl phosphate (ρNPP) 
substrate (Invitrogen) was added. Optical densities 
were recorded at 410 nm on an OPTImax tunable 
microplate reader (Molecular Devices Corp., 
Sunnyvale, CA). 
Detection of antibodies to BMP4 and BMP6 
Microtiter plates (96-well, Nunc) were coated 
with the purified human BMP4 and BMP6 (R&D 
Systems, Minneapolis, MN), followed by blocking, as 
described earlier. Rat sera were added in serial 
dilutions. Captured antibodies were detected as 
described previously. 
3.  RESULTS 
Cloning, sequencing, and identification of rat BMP4 and 
BMP6 cDNAs 
Rat BMP4 and BMP6 cDNA fragments 
containing complete coding regions were amplified by 
RT-PCR from the total spleen RNA of an adult SD rat. 
Afterward the fragments were directly cloned into 
pShuttleCMV, which is a transfer vector used with the 
CMV promoter for the pAdEasy Vector System.  
For rat BMP4 cDNA, five recombinant plasmids 
were selected and transfected into 293A cells. The 
expression of BMP4 was determined by performing 
immunocytochemical staining and Western blot 
analysis. Three of the five clones produced and 
secreted BMP4, but the amounts of BMP4 expressed 
by these clones varied; the other two clones could not 
produce BMP4 (Fig. 1). The three clones with BMP4 
expression were sequenced and their sequences were 
compared with the BMP4 coding region sequence 
published in GenBank. Only three consecutive base 
pairs in the propeptide coding region differed from 
the rat BMP4 sequence described by GenBank, but 
these base pairs were the same as those found in 
murine and human BMP4. One clone that 
demonstrated a high BMP4 expression was used to 
construct the rat BMP4 recombinant adenoviral vector. 
The complete rat BMP4 cDNA sequence was 
submitted to GenBank (accession No. AY184241).  
Figure 1 Western blot detection of rat BMP4 or BMP6 
in conditioned media. The conditioned media were 
prepared from 293A cells transfected with rat BMP4 or 
BMP6 cDNA recombinant clones. Detection was 
accomplished using BMP4 antibody (upper panel) and 
BMP6 antibody (lower panel). Lane 1, pShuttleCMV; 
Lanes 2–6, rat BMP4 or BMP6 recombinant clones; Lane 7, 
pShuttle-hBMP4 or pShuttle-hBMP6. 
 
 
For rat BMP6 cDNA, five recombinant plasmids 
(Nos. 1, 2, 7, 8, and 23] and the purified PCR product 
were sequenced. The clones differed from each other 
and from the partial sequence of the rat BMP6 gene 
published in GenBank. Only clone No. 8 could 
produce and secrete BMP6, as observed using 
immunocytochemical staining and Western blot 
analysis (Fig. 1). Based on a comparison of the BMP6 
sequences of the five clones and the purified PCR 
product, the first complete rat BMP6 cDNA sequence 
was obtained and submitted to GenBank (accession 
No. AY184240). For the derived amino acid sequence, 
amino acids 301 through 506 are identical to those 
derived from the previously reported partial sequence 
for the Lewis rat [39] (GenBank accession No. X58830), 
and amino acids 77 through 280 are identical to those 
derived from the previously reported partial sequence 
for the Wistar rat [22] (GenBank accession No. U66298) 
except for amino acid 146, which in our sequence is 
valine as opposed to alanine in the Wistar rat. The 
remaining amino acids, 1 through 76 and 281 through 
300, are identical to those found in the mouse  [8, 16, 
17, 28] (GenBank accession No. NM_007556). To Int. J. Med. Sci. 2006, 3  101
ensure that the sequence of rat BMP6 cDNA was 
correct,  BMP6 cDNA from another SD rat was 
amplified, cloned, and sequenced. The findings 
confirmed that the BMP6 sequences from the two rats 
were identical. Genomic DNA containing the codon 
for the polymorphic amino acid was amplified from 
four additional SD rats and sequenced. The results of 
the genomic sequencing also verified the presence of 
valine at position 146 in the SD rats.  
In each of the five rat BMP6 clones one or several 
amino acids were mutated, even though clone No. 8 
could produce and secrete BMP6. A rat BMP6 
recombinant clone was generated by ligation at the 
EcoNI site, between the upstream segment of clone No. 
8 and the downstream segment of clone No. 2, to 
obtain a complete clone with no mutated amino acid.  
Construction and identification of ADrBMP4 and 
ADrBMP6  
The AdEasy system was used to construct 
ADrBMP4 and ADrBMP6. The viral DNA of 
ADrBMP4 and ADrBMP6 were identified by 
performing a Southern blot analysis. Figure 2 shows 
the Southern blot for BMP6. The viral DNA contained 
the correct rat BMP cDNA inserts, and the expected 
DNA fragments were generated by using several 
restriction endonucleases. The titers of the purified 
viral solutions were 1.0 × 1012 particles/ml or 2.1 × 
1010 plaque forming units (PFU)/ml for ADrBMP4 and 
2.7 × 1012 particles/ml or 3.3 ×1010 PFU/ml for 
ADrBMP6.  
Figure 2 Identification of recombinant BMP6 
adenoviruses by Southern Blot analysis. A. pAdEasy1 
probe. B. BMP6 cDNA fragment probe. DNA samples were 
digested by HindIII (Lanes 1, 2 and 3), BstXI (Lanes 4, 5, 
and 6), and BglII plus EcoRV (Lanes 7, 8, and 9). M, 1-kb 
DNA ladder. Lanes 1, 4, and 7, 293A cells; Lanes 2, 5, and 
8, ADrBMP6 DNA; Lanes 3, 6, and 9, ADhBMP6 DNA. 
This finding indicates that the construction of rat BMP6 
recombinant adenovirus is correct. 
 
 
BMP4 and BMP6 expression by corresponding 
adenoviral vectors in Vero cells 
Protein expression by the BMP4 vectors is 
demonstrated in Fig. 3A and B, which depicts the 
results of a Western blot analysis of lysed Vero cells 
transduced with ADNULL, ADhBMP4, or ADrBMP4. 
The blot was tested with BMP4 antibody (Fig. 3A) and 
with  β-actin antibody (Fig. 3B). The ADrBMP4-
transduced cells produced mature protein that 
exhibited the same electrophoretic mobility as 
ADhBMP4 on a reduced gel. There was no significant 
difference in the amount of BMP4 expressed by 
ADrBMP4- and ADhBMP4-transduced Vero cells. 
Protein expression by the BMP6 vectors is 
demonstrated in Fig. 3C, which shows a Western blot 
of lysed Vero cells transduced with ADNULL, 
ADhBMP6, or ADrBMP6. The blot was probed with 
an antibody to BMP6 (Fig. 3C) and with β-actin 
antibody (Fig. 3D). The ADrBMP6-transduced cells 
produced mature protein that exhibited the same 
electrophoretic mobility as ADhBMP6 on a reduced 
gel. Also there was no significant difference in the 
amounts of expressed BMP6 protein between 
ADrBMP6- and ADhBMP6-transduced Vero cells, 
which were 8.1 μg/ml and 7.9 μg/ml, respectively. 
After a denaturing gel electrophoresis under reducing 
conditions and a Western blot analysis, a 19-kD 
protein reacted with the BMP6 antibody. The staining 
differed from that of standard human BMP6, which 
was purchased from R&D Systems (Minneapolis, MN) 
and displayed two bands at 18 kD and 23 kD. This 
difference may be due to dissimilar cell types, which 
may produce different numbers of glycosylation sites.  
Alkaline phosphatase activity induced by BMP 
adenoviral vectors in C2C12 cells  
To evaluate the biological function of rat and 
human BMP4 and BMP6, C2C12 cells transduced with 
BMP adenoviral vectors were stained to demonstrate 
alkaline 
phosphatase 
(ALP) activity, 
which is an 
important 
indicator of 
BMP activity. 
The 
ADrBMP4-
induced ALP 
expression in 
C2C12 cells 
was similar to 
that observed 
following 
ADhBMP4 
treatment 
(data not 
shown); 
however, at 
the same number of viral particles, the ALP expression 
induced by ADrBMP6 in C2C12 cells was significantly Int. J. Med. Sci. 2006, 3  102
less than that induced by ADhBMP6 (Fig. 4). No ALP 
was detected in ADNULL-transduced cells. 
Figure 3 Western blot detection of BMP4 (A), BMP6 (C 
and E), and β-actin (B and D). A solution of lyzed 
transduced Vero cells (A, B, C, and D) or conditioned 
medium (E) was loaded onto the reduced gel;  A. BMP4 
antibody detection: Lane 1, Rainbow protein molecular 
marker; Lane 2, untreated cells; Lane 3, ADNULL; Lane 4, 
ADhBMP4; Lane 5, ADrBMP4; Lane 6, [E1-,E2b-
]ADGFP&hBMP4; Lanes 7, 8 and 9, BMP4 protein 
standards 20, 10, and 5 ng. B. The same blot as A tested 
with β-actin antibody. C. BMP6 antibody: Lane 1, Rainbow 
protein molecular marker; Lane 2, untreated cells; Lane 3, 
ADNULL; Lane 4, ADhBMP6; Lane 5, ADrBMP6; Lanes 
6, 7, and 8, BMP6 protein standards 10, 20, and 40 ng. D. 
The same blot as C probed with β-actin antibody. E. BMP6 
antibody detection: Lane 1, Rainbow protein molecular 
marker; Lane 2, untreated cells; Lane 3, ADNULL; Lane 4, 
[E1-,E2b-]ADhBMP6; Lane 5, [E1-,E2b-]ADGFP&hBMP6; 
Lane 6, ADhBMP6. 
 
 
Figure 4 Alkaline phosphatase activity of BMP6 
adenoviruses in C2C12 cells. The C2C12 cells  were 
transduced with AdCMV-Null, AdCMV-rBMP6 or 
AdCMV-hBMP6 particles 3x10
8 (A), 1.5x10
8 (B), 7.5x10
7 
(C) and 3.8x10
7 (D). 
 
Construction and identification of [E1-, E2b-]ADhBMPs 
Human  BMP4 and BMP6 cDNAs were also 
inserted into second-generation adenoviral vectors. 
These vectors, which included [E1-,E2b-
]ADGFP&hBMP4, [E1-,E2b-]ADhBMP6, and [E1-,E2b-
]ADGFP&hBMP6, were validated by PCR, RT-PCR, 
and Southern blot analysis. The titers of the purified 
[E1-,E2b-]ADGFP&hBMP4, [E1-,E2b-]ADhBMP6, and 
[E1-,E2b-]ADGFP&hBMP6 were 8.6 × 1011, 9.6 × 1011, 
and 3.6 × 1011 particles/ml, respectively. The amounts 
of human BMP4 and BMP6 expression in the [E1-,E2b-
]ADhBMPs were also compared in Vero cells. Similar 
amounts of mature BMP4 were detected in solutions 
of lysed cells that had contained [E1-,E2b-
]ADGFP&hBMP4 and ADhBMP4 (Fig. 3A and B), and 
similar amounts of secreted mature BMP6 were 
detected in cultured media that had contained [E1-
,E2b-]ADhBMP6, [E1-,E2b-]ADGFP&hBMP6, and 
ADhBMP6 (Fig. 3E).  
Ectopic bone formation induced by BMP adenoviral 
vectors 
On Day 35 after viral injection, the rats 
underwent computerized tomography (CT) scanning, 
and three-dimensional reconstruction was performed 
using a Voxel Q workstation. The sites at which 
ADhBMP4, ADrBMP4, and [E1-,E2b-]ADGFP&hBMP4 
had been injected into AN rats revealed similar 
volumes of ectopic bone formation. None of the BMP4 
adenoviruses induced ectopic bone formation at the 
injection site in SD rats, and ADNULL did not induce 
ectopic bone formation at the injection site in AN or 
SD rats (Fig. 5 upper panel). In AN rats ectopic bone 
formation was found in the thigh musculature 
adjacent to the femur, at the injection sites of 
ADrBMP6 and ADhBMP6. At the same viral dose (2.8 
× 1010 particles) the mean volume of bone induced by 
ADhBMP6 in these animals was larger than that 
induced by ADrBMP6. Mean bone volumes were 
greater in AN rats that had received increased viral 
doses of ADrBMP6 (Table 1). In SD rats, ectopic bone 
formation was shown at sites that had been injected 
with 1.4 × 1011 particles of ADrBMP6 and 2.8 
×1010 particles of ADhBMP6, but not at the site 
that had been injected with 2.8 × 1010 particles of 
A D r B M P 6 .  B o n e  v o l u m e s  i n  S D  r a t s  t h a t  h a d  
received one of these two BMP6 vectors were 
significantly smaller than volumes measured in 
AN rats that received the same viral dose (Fig. 5 
lower panel). Similar patterns of bone formation 
for [E1-,E2b-]ADhBMP6 and [E1-,E2b-
] A D G F P & h B M P 6  w e r e  o b s e r v e d  i n  b o t h  A N  
and SD rats. Int. J. Med. Sci. 2006, 3  103
Figure 5 BMP4- and BMP6-induced bone formation in 
AN and SD rats. The animals were scanned on Day 35 
after viral injection. The viral dose was 5 × 10
10 particles/50 
µl for all BMP4 vectors (upper panel), 2.8 × 10
10 
particles/50 µl for ADhBMP6 and 1.4 × 10
11 particles/50 µl 
for ADrBMP6 (lower panel), and 5 × 10
10 (upper panel) and 
1.4 × 10
11  (lower panel) particles/50 µl for ADNULL. 
Arrows indicate ectopic bone formation. 
 
Table 1. Volumes of new bone induced by different BMP6 
adenoviruses in AN and SD rats. 
Adenovirus  New Bone in  
AN Rats (cm3) 
New Bone in SD Rats (cm3) 
ADNULL 
(2.8×1010 particles) 
0 0 
ADhBMP6 
(2.8×1010 particles) 
1.02±0.07 0.08±0.02 
ADrBMP6 
(2.8×1010 particles) 
0.48±0.09 0 
ADrBMP-6 
(1.4×1011 particles) 
1.06±0.05 0.07±0.03 
Detection of BMP4 and BMP6 antibodies 
Enzyme-linked immunosorbent assays (ELISAs) 
were used to analyze sera obtained from the SD rats to 
determine the presence of antibodies against the 
adenovirus and against BMP4 and BMP6. Sera from 
ADNULL-, ADrBMP6-, ADhBMP6 -injected SD rats 
contained equivalent titers of adenovirus antibodies 
(Fig. 6A). Sera from ADhBMP6-injected SD rats 
demonstrated significant antibodies against BMP6, 
and sera from ADrBMP6-injected rats contained 
similar titers of antibodies to BMP6 (Fig. 6B). Sera 
from ADNULL-injected rats contained negligible 
antibodies to BMP6.  
Similarly, sera from ADNULL-, ADhBMP4- and 
ADrBMP4-injected rats contained equivalent titers of 
adenovirus antibodies. Sera from ADhBMP4-injected 
SD rats demonstrated antibodies against BMP4 and, 
unexpectedly, sera from ADrBMP4-injected SD rats 
contained similar titers of antibodies to BMP4. Sera 
from ADNULL-injected SD rats exhibited no reaction 
to BMP4 (data not shown). 
Figure 6 Relative titers of adenovirus and BMP6 antibodies 
among BMP6 vector– injected SD rats. The SD rat sera 
were collected on Day 35 after viral injection and tested at 
a 1:320 dilution by using an ELISA. A. Adenovirus 
antibody. B. BMP6 antibody. 
 
4.  DISCUSIONS 
Although many papers have provided evidence 
that second- or third-generation adenoviral vectors 
reduce the host immune response and prolong the 
expression of transduced foreign genes in 
immunocompetent animals compared with first-
generation adenoviral vector, this does not 
significantly affect the fate of BMP adenoviral vectors 
in immunocompetent animals. In our previous report 
[23], we showed that a helper-dependent adenoviral 
vector did not improve the osteogenic potential of the 
BMP9 in immunocompetent animals. Because there is 
a certain amount of helper virus contamination in the 
preparation of a BMP9 helper-dependent adenovirus 
and because BMP4, BMP6, and BMP9 have different 
signal transduction pathways, the effects of viral gene 
expression in transfected cells on BMP-induced bone 
formation remained unclear. As a consequence the 
present study was designed and performed. 
Recombinant human BMP4 and BMP6 second-
generation adenoviral vectors have not shown any 
improvement in the induction of ectopic bone 
formation in immunocompetent rats. The results of 
our other experiments demonstrate that foreign gene Int. J. Med. Sci. 2006, 3  104
expression curves are very similar in AN and SD rats 
when a first-generation adenovirus is used. Periods of 
foreign gene (luciferase) expression can last up to 9 
months in SD rats and 6 months in rabbits [24]. The 
findings indicate that, although similar amounts of 
BMP4 or BMP6 may be expressed by their adenoviral 
vectors in AN and SD rats, the osteogenic potentials of 
BMP4 or BMP6 are significantly reduced in 
immunocompetent rats. This limitation may be caused 
by the innate host immune response, rather than by 
the adaptive immune response, which is induced by a 
direct injection of viral particles [14, 15, 32]. T cells or 
their secreted cytokines may play critical roles in the 
process of bone formation.  
The source of the foreign genes is another 
possible factor that may determine the fate of BMP 
adenoviral vectors. To assess the potential immune 
response against foreign human BMP, rat BMP4 and 
BMP6 cDNAs were amplified, cloned, sequenced, and 
identified. Recombinant adenoviruses encoding rat 
BMP4 and BMP6  were constructed and compared 
with ADhBMP4 and ADhBMP6 in the in vitro and in 
vivo models. At the same viral dose, the activities of 
rat and human BMP4 adenoviral vectors are very 
similar in all models. Nevertheless, the activity of rat 
BMP6 is lower than that of human BMP6 in all three 
models; this is apparent because lower amounts of 
ALP and smaller volumes of bone were induced by 
ADrBMP6 than by ADhBMP6 in AN and SD rats. The 
results indicate that the source of the BMP gene is not 
a major factor affecting the osteogenic potential of 
BMP adenoviral vectors in immunocompetent animals. 
On the other hand, the process of bone formation can 
be initiated by BMP adenoviral vectors within 1 to 3 
days after viral injection [1, 21, 23, 43]. This indicates 
that the early stage after BMP viral injection is the 
critical period in which to determine the functions of 
BMP adenoviral vectors in immunocompetent animals. 
Any additional investigations undertaken to improve 
the potentials of BMP vectors should target this early 
stage.  
Induction of the host immune response by 
foreign gene products is a basic immunological 
principle; however, induction of the host immune 
response by homologous gene products rarely occurs. 
In our experiment, BMP4 and BMP6 antibodies in SD 
rats were detected in the presence of not only 
ADhBMP4 and ADhBMP6, but also ADrBMP4 and 
ADrBMP6. It remains unclear why this autoimmune 
response occurred, but one possible reason may be 
that local over expression of rat BMPs in muscle tissue 
provoked the host immune system. Another reason 
for this autoimmunity may be directly connected to 
adenoviral vector infection of the muscle cells. It has 
been shown that adenoviral infections can break the 
host’s  tolerance to peripheral transgene-encoded 
antigens [37, 47], and injection of a foreign protein in 
adjuvant has been shown to break the host’s tolerance 
to a homologous self protein [26, 29]. It has been 
demonstrated that adenoviral vectors can also induce 
immune responses to self-antigens [41]. Interestingly, 
mice that are transgenic for an E1,E3–deleted 
adenoviral genome do not appear to tolerate first-
generation adenoviral vectors, and exposure to 
adenoviral antigens still elicits the generation of a 
robust immune response [7]. The overexpression of 
self-transgenes may, therefore, lead to an autoimmune 
response and potentially significant side-effects. Thus, 
human gene therapy trials in which an adenoviral 
vector containing human genes is utilized should be 
pursued with caution. Further study of this 
mechanism may be helpful to understand 
autoimmune diseases in the human clinical setting.  
Besides the aforementioned major findings of 
this experiment, accurate gene sequencing is also a 
critical factor in the determination of the fate of gene 
expression. Any mismatched base pair may lead to the 
inability of a gene to express its protein. This issue 
should be emphasized, especially when cDNA is 
amplified using RT-PCR.  
In conclusion, although the deletion of the E1 
and E2b genes and the use of homologous (rat) BMP 
genes do not improve the osteogenic potential of 
direct BMP adenovirus vector gene therapy, the 
results of this study indicate that BMP gene therapy 
has unique characteristics and that the initial immune 
response may play a critical role in the process of bone 
formation. Interestingly, ADrBMP4 and ADrBMP6 
treatments led to the production of anti-self (anti-
rBMP4 or anti-rBMP6) antibodies.  
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